Aurobindo Pharma in lead to acquire Zentiva for US 5.5 billion: ET Report
Indian drug giant Aurobindo Pharma is reportedly leading the race to acquire Prague-based drugmaker Zentiva in a deal that could be worth up to $5.5 billion, according to a report by The Economic Times on Wednesday. If finalized, the acquisition would mark the largest-ever buyout by an Indian pharmaceutical company.
Aurobindo is in talks with U.S.-based private equity firm Advent International, which owns Zentiva, the report said, citing people aware of the matter.
However, Aurobindo issued a clarification in a statement to stock exchanges, saying that no binding agreements have been signed by the company’s board as of yet.
Read also: Aurobindo Pharma ramps up China facility production, eyes Q3 FY26 break even
In July, the company's wholly owned subsidiary, Aurobindo Pharma USA Inc, entered into a definitive agreement to acquire 100% membership interest in Lannett Company LLC from Lannett Seller Holdco Inc.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.